Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study.

Publication

Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study.

Journal Paper/Review - Jul 25, 2024

Fleischmann Roy, Meerwein Sebastian, Charles-Schoeman Christina, Combe Bernard, Hall Stephen, Khan Nasser, Carter Kyle M, Camp Heidi S, Rubbert-Roth Andrea

Citation

Fleischmann R, Meerwein S, Charles-Schoeman C, Combe B, Hall S, Khan N, Carter K, Camp H, Rubbert-Roth A. Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study. RMD Open 2024; 10

Type

Journal Paper/Review (English)

Journal

RMD Open 2024; 10

Publication Date

Jul 25, 2024

Issn Electronic

2056-5933

Brief description/objective

To evaluate the efficacy and safety of upadacitinib over 5 years among patients with rheumatoid arthritis (RA) in a long-term extension (LTE) of the SELECT-BEYOND phase 3 trial.